ArticleThe Journal of experimental medicine1999
Immune privilege: keeping an eye on natural killer T cells.
Article in The Journal of experimental medicine, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Chemokine gradients spare graft endothelium from CD8+ T cell-mediated injury during allograft rejection.The Journal of clinical investigation · 2025Article
- Fibrotic Changes in Rhegmatogenous Retinal Detachment.International journal of molecular sciences · 2025Review
- Heterogeneity and molecular landscape of melanoma: implications for targeted therapy.Molecular biomedicine · 2024Review
- Cancer testis antigen burden (CTAB): a novel biomarker of tumor-associated antigens in lung cancer.Journal of translational medicine · 2024Article
- Morphology of the immune cells in the wall of the human uterine tube and their possible impact on reproduction-uterine tube as a possible immune privileged organ.Frontiers in cell and developmental biology · 2024Review
- Ocular Vascular Diseases: From Retinal Immune Privilege to Inflammation.International journal of molecular sciences · 2023Review
- Review
- The ciliary zonules provide a pathway for immune cells to populate the avascular lens during eye development.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Somatic-Immune Cells Crosstalk In-The-Making of Testicular Immune Privilege.Reproductive sciences (Thousand Oaks, Calif.) · 2022Review
- Immune-mediated alopecias and their mechanobiological aspects.Cells & development · 2022Review
- Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.Molecular cancer · 2022Review
- Jigsaw falling into place: A review and perspective of lymphoid tissue CD8+ T cells and control of HIV.Molecular immunology · 2020Review
- Human Cytomegalovirus (HCMV)-infected Astrocytoma Cells Impair the Function of HCMV-specific Cytotoxic T Cells.Journal of Korean medical science · 2020Article
- Migration and Function of Memory CD8The Journal of investigative dermatology · 2020Review
- Immune Privilege Collapse and Alopecia Development: Is Stress a Factor.Skin appendage disorders · 2018Review
- Immune barriers of Ebola virus infection.Current opinion in virology · 2018Review
- Panel 3: Genetics and Precision Medicine of Otitis Media.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2017Review
- Expression of lectin-like transcript-1 in human tissues.F1000Research · 2016Article
- Banking on iPSC--is it doable and is it worthwhile.Stem cell reviews and reports · 2015Article
- Cellular-based immunotherapies for patients with glioblastoma multiforme.Clinical & developmental immunology · 2012Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.